+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Retroviral Drugs Market by Product Type (Ccr5 Antagonists, Fusion Inhibitors, Integrase Strand Transfer Inhibitors), Route Of Administration (Oral, Parenteral), Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast 2025-2030- Product Image
Anti-Retroviral Drugs Market by Product Type (Ccr5 Antagonists, Fusion Inhibitors, Integrase Strand Transfer Inhibitors), Route Of Administration (Oral, Parenteral), Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast 2025-2030- Product Image
Sale

Anti-Retroviral Drugs Market by Product Type (Ccr5 Antagonists, Fusion Inhibitors, Integrase Strand Transfer Inhibitors), Route Of Administration (Oral, Parenteral), Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015172
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-retroviral drugs market continues to evolve rapidly as scientific advances, regulatory reforms, and patient expectations converge to reshape global HIV treatment paradigms. Industry leaders navigating this dynamic landscape require an understanding of shifting therapeutic models, access trends, and emerging competitive strategies to remain agile and drive sustainable growth.

Market Snapshot: Anti-Retroviral Drugs Market Overview

The anti-retroviral drugs market grew from USD 29.05 billion in 2024 to USD 30.44 billion in 2025. It is expected to maintain steady expansion, achieving a CAGR of 4.63% and reaching USD 38.13 billion by 2030. This sustained growth reflects ongoing investment in next-generation therapies and the adoption of new care delivery models worldwide.

Scope & Segmentation of the Anti-Retroviral Drugs Market

  • Product Types: CCR5 antagonists; fusion inhibitors; integrase strand transfer inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside reverse transcriptase inhibitors; protease inhibitors
  • Routes of Administration: Oral; parenteral
  • Formulations: Injectable (intravenous, subcutaneous); oral solid (tablet, capsule); oral liquid (solution, suspension)
  • End Users: Home care; hospitals; specialty clinics
  • Distribution Channels: Hospital pharmacies; online pharmacies; retail pharmacies
  • Therapy Lines: First line; second line; salvage therapy
  • Patient Groups: Adult; pediatric
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Gilead Sciences, Inc.; ViiV Healthcare ULC; Johnson & Johnson; Merck & Co., Inc.; Bristol-Myers Squibb Company; Teva Pharmaceutical Industries Ltd.; Viatris Inc.; Cipla Limited; Aurobindo Pharma Limited; Lupin Limited

Key Takeaways for Stakeholders

  • Recent innovation is driven by scientific breakthroughs in long-acting injectable therapies, oral formulation advancements, and gene editing approaches, which offer the potential to address adherence and quality-of-life concerns.
  • Patient-centric models and decentralized care settings are enhancing engagement and supporting real-world outcomes, with digital health tools gaining momentum for adherence monitoring and patient education.
  • Regional nuances affect access, with advanced biopharmaceutical infrastructure in the Americas facilitating rapid therapy adoption, while collaborative initiatives and tiered pricing strategies are crucial in Europe, Middle East & Africa, and Asia-Pacific markets.
  • Industry players are leveraging strategic alliances, licensing models, and partnerships with contract manufacturers to optimize supply chain resilience and accelerate market entry, particularly amid evolving global trade conditions.
  • Segmented approaches—addressing both adult and pediatric patient groups, as well as diverse therapy lines—are key for market penetration and ensuring equitable treatment outcomes across demographics.

Tariff Impact: Navigating U.S. Regulatory Changes

Planned United States tariff changes for 2025 are anticipated to influence global anti-retroviral drug supply chains and manufacturer pricing. Upstream costs for generics may rise, pushing manufacturers to consider alternative sourcing, domestic production partnerships, and collaborative advocacy efforts to maintain affordability. As a result, proactive adaptation in procurement strategies will be essential for sustained patient access and market competitiveness.

Methodology & Data Sources

This report utilizes a hybrid approach, combining primary interviews with key opinion leaders, biopharma executives, and patient advocacy representatives, alongside systematic review of secondary data from peer-reviewed publications, regulatory filings, and trade databases. Analytical frameworks including scenario and sensitivity analyses ensure robust insight for reliable decision-making.

Why This Report Matters: Actionable Insights for Senior Decision-Makers

  • Benchmark portfolio and strategic planning against evolving treatment modalities, regulatory landscapes, and regional growth corridors.
  • Identify critical opportunities in emerging delivery systems, patient engagement platforms, and supply chain optimization strategies.
  • Inform go-to-market tactics by understanding shifting therapeutic preferences and competitive positioning of key industry players.

Conclusion

Senior executives evaluating the anti-retroviral drugs market benefit from an integrative view of innovation, segmentation, and regional dynamics shaping the sector. This analysis provides a foundation for strategic actions driving sustained growth and access in a competitive, evolving environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of long-acting injectable antiretroviral regimens improving patient adherence
5.2. Increasing adoption of two-drug maintenance therapies reducing long-term toxicity risks
5.3. Rapid uptake of generic tenofovir alafenamide formulations lowering treatment costs
5.4. Integration of digital adherence monitoring platforms into HIV care programs
5.5. Expansion of pediatric antiretroviral dosing guidelines to improve child outcomes
5.6. Ongoing development of broadly neutralizing antibody therapies for HIV management
5.7. Regulatory approvals driving uptake of bictegravir-based single-tablet regimens in markets
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Retroviral Drugs Market, by Product Type
8.1. Introduction
8.2. Ccr5 Antagonists
8.3. Fusion Inhibitors
8.4. Integrase Strand Transfer Inhibitors
8.5. Non-Nucleoside Reverse Transcriptase Inhibitors
8.6. Nucleoside Reverse Transcriptase Inhibitors
8.7. Protease Inhibitors
9. Anti-Retroviral Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Anti-Retroviral Drugs Market, by Formulation
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral Liquid
10.3.1. Solution
10.3.2. Suspension
10.4. Oral Solid
10.4.1. Capsule
10.4.2. Tablet
11. Anti-Retroviral Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Specialty Clinics
12. Anti-Retroviral Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Anti-Retroviral Drugs Market, by Therapy Line
13.1. Introduction
13.2. First Line
13.3. Salvage Therapy
13.4. Second Line
14. Anti-Retroviral Drugs Market, by Patient Group
14.1. Introduction
14.2. Adult
14.3. Pediatric
15. Americas Anti-Retroviral Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Anti-Retroviral Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Anti-Retroviral Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Gilead Sciences, Inc.
18.3.2. ViiV Healthcare ULC
18.3.3. Johnson & Johnson
18.3.4. Merck & Co., Inc.
18.3.5. Bristol-Myers Squibb Company
18.3.6. Teva Pharmaceutical Industries Ltd.
18.3.7. Viatris Inc.
18.3.8. Cipla Limited
18.3.9. Aurobindo Pharma Limited
18.3.10. Lupin Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ANTI-RETROVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ANTI-RETROVIRAL DRUGS MARKET: RESEARCHAI
FIGURE 30. ANTI-RETROVIRAL DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. ANTI-RETROVIRAL DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. ANTI-RETROVIRAL DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 129. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 134. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 135. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 136. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 137. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 138. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 251. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 256. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 257. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 258. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 259. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 260. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 261. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 262. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 263. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 268. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 269. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 270. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 271. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 276. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 277. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 278. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 279. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 280. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 281. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 282. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 283. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 288. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 289. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 290. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 311. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 316. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 317. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 318. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 319. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
TABLE 320. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2030 (USD MILLION)
TABLE 321. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
TABLE 322. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2030 (USD MILLION)
TABLE 323. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 328. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 329. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 330. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 331. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Anti-Retroviral Drugs market report include:
  • Gilead Sciences, Inc.
  • ViiV Healthcare ULC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Lupin Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 30.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.13 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Retroviral Drugs - Global Strategic Business Report - Product Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Anti-Retroviral Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Anti-Retroviral Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 95 Pages
  • Global
From
2025 Global Forecast for Anti-Retroviral Drugs (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Anti-Retroviral Drugs (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
HIV Antivirals Market by Drug Class (CCR5 Antagonists, Fusion Inhibitors, Integrase Strand Transfer Inhibitors), Product Type (Fixed Dose Combination, Single Agent), Distribution Channel, Formulation Type, Therapy Line, Brand Type, Patient Age Group - Global Forecast 2025-2030 - Product Image

HIV Antivirals Market by Drug Class (CCR5 Antagonists, Fusion Inhibitors, Integrase Strand Transfer Inhibitors), Product Type (Fixed Dose Combination, Single Agent), Distribution Channel, Formulation Type, Therapy Line, Brand Type, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
HIV Entry Inhibitors Market by Mechanism of Action (Ccr5 Antagonists, Fusion Inhibitors, Post-Attachment Inhibitors), Route of Administration (Injectable, Oral), End User, Distribution Channel, Patient Type - Global Forecast 2025-2030 - Product Image

HIV Entry Inhibitors Market by Mechanism of Action (Ccr5 Antagonists, Fusion Inhibitors, Post-Attachment Inhibitors), Route of Administration (Injectable, Oral), End User, Distribution Channel, Patient Type - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From

About the Antiretroviral Market

The antiretroviral market is a subset of the HIV/AIDS drugs market, which is focused on the development and sale of drugs that can be used to treat HIV/AIDS. Antiretroviral drugs are used to reduce the amount of HIV in the body, and can be used to prevent the transmission of HIV from one person to another. These drugs are typically used in combination with other treatments, such as counseling and lifestyle changes, to help people living with HIV/AIDS manage their condition. The antiretroviral market is highly competitive, with many companies developing and selling drugs to treat HIV/AIDS. Some of the major players in the market include Gilead Sciences, Merck, Bristol-Myers Squibb, GlaxoSmithKline, and ViiV Healthcare. Other companies, such as AbbVie, Janssen, and Mylan, also have a presence in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.